The echinocandin antifungals: An overview of the pharmacology, spectrum and clinical efficacy

Nathan Wiederhold, Russell E. Lewis

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

For over four decades, the principal target of antifungal therapy has been the fungal cell membrane sterol ergosterol. Although this has proven to be a successful and relatively selective antifungal target, collateral toxicity to mammalian cells (amphotericin B) and drug interactions (azoles) have been by-products of agents that target the fungal cell membrane. In the 1970s, the echinocandins were identified during the screening of fungal fermentation products for new antibiotic agents. These agents were subsequently shown to inhibit production of β(1,3)-glucan, a key structural component of the fungal cell wall. Subsequent chemical modification of these natural products has led to the development of safer, semi-synthetic β(1,3)-glucan synthase inhibitors with enhanced microbiological and clinical efficacy against infections caused by Candida and Aspergillus species. In this review, the pharmacology, spectrum and clinical efficacy of the three leading β(1,3)-glucan synthase inhibitors (caspofungin, micafungin and anidulafungin), which have completed phase III clinical trials, will be discussed and a perspective for the role of these agents in the management of life-threatening mycoses will be offered.

Original languageEnglish (US)
Pages (from-to)1313-1327
Number of pages15
JournalExpert Opinion on Investigational Drugs
Volume12
Issue number8
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Echinocandins
caspofungin
anidulafungin
Cell Membrane
Fungal Structures
Pharmacology
Ergosterol
Azoles
Phase III Clinical Trials
Glucans
Mycoses
Amphotericin B
Sterols
Aspergillus
Biological Products
Drug Interactions
Candida
Cell Wall
Fermentation
Anti-Bacterial Agents

Keywords

  • Anidulafungin
  • Aspergillus
  • Candida
  • Caspofungin
  • Micafungin

ASJC Scopus subject areas

  • Pharmacology

Cite this

The echinocandin antifungals : An overview of the pharmacology, spectrum and clinical efficacy. / Wiederhold, Nathan; Lewis, Russell E.

In: Expert Opinion on Investigational Drugs, Vol. 12, No. 8, 01.08.2003, p. 1313-1327.

Research output: Contribution to journalArticle

@article{293e78b8af7e441ea6da0c8501c19721,
title = "The echinocandin antifungals: An overview of the pharmacology, spectrum and clinical efficacy",
abstract = "For over four decades, the principal target of antifungal therapy has been the fungal cell membrane sterol ergosterol. Although this has proven to be a successful and relatively selective antifungal target, collateral toxicity to mammalian cells (amphotericin B) and drug interactions (azoles) have been by-products of agents that target the fungal cell membrane. In the 1970s, the echinocandins were identified during the screening of fungal fermentation products for new antibiotic agents. These agents were subsequently shown to inhibit production of β(1,3)-glucan, a key structural component of the fungal cell wall. Subsequent chemical modification of these natural products has led to the development of safer, semi-synthetic β(1,3)-glucan synthase inhibitors with enhanced microbiological and clinical efficacy against infections caused by Candida and Aspergillus species. In this review, the pharmacology, spectrum and clinical efficacy of the three leading β(1,3)-glucan synthase inhibitors (caspofungin, micafungin and anidulafungin), which have completed phase III clinical trials, will be discussed and a perspective for the role of these agents in the management of life-threatening mycoses will be offered.",
keywords = "Anidulafungin, Aspergillus, Candida, Caspofungin, Micafungin",
author = "Nathan Wiederhold and Lewis, {Russell E.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1517/13543784.12.8.1313",
language = "English (US)",
volume = "12",
pages = "1313--1327",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - The echinocandin antifungals

T2 - An overview of the pharmacology, spectrum and clinical efficacy

AU - Wiederhold, Nathan

AU - Lewis, Russell E.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - For over four decades, the principal target of antifungal therapy has been the fungal cell membrane sterol ergosterol. Although this has proven to be a successful and relatively selective antifungal target, collateral toxicity to mammalian cells (amphotericin B) and drug interactions (azoles) have been by-products of agents that target the fungal cell membrane. In the 1970s, the echinocandins were identified during the screening of fungal fermentation products for new antibiotic agents. These agents were subsequently shown to inhibit production of β(1,3)-glucan, a key structural component of the fungal cell wall. Subsequent chemical modification of these natural products has led to the development of safer, semi-synthetic β(1,3)-glucan synthase inhibitors with enhanced microbiological and clinical efficacy against infections caused by Candida and Aspergillus species. In this review, the pharmacology, spectrum and clinical efficacy of the three leading β(1,3)-glucan synthase inhibitors (caspofungin, micafungin and anidulafungin), which have completed phase III clinical trials, will be discussed and a perspective for the role of these agents in the management of life-threatening mycoses will be offered.

AB - For over four decades, the principal target of antifungal therapy has been the fungal cell membrane sterol ergosterol. Although this has proven to be a successful and relatively selective antifungal target, collateral toxicity to mammalian cells (amphotericin B) and drug interactions (azoles) have been by-products of agents that target the fungal cell membrane. In the 1970s, the echinocandins were identified during the screening of fungal fermentation products for new antibiotic agents. These agents were subsequently shown to inhibit production of β(1,3)-glucan, a key structural component of the fungal cell wall. Subsequent chemical modification of these natural products has led to the development of safer, semi-synthetic β(1,3)-glucan synthase inhibitors with enhanced microbiological and clinical efficacy against infections caused by Candida and Aspergillus species. In this review, the pharmacology, spectrum and clinical efficacy of the three leading β(1,3)-glucan synthase inhibitors (caspofungin, micafungin and anidulafungin), which have completed phase III clinical trials, will be discussed and a perspective for the role of these agents in the management of life-threatening mycoses will be offered.

KW - Anidulafungin

KW - Aspergillus

KW - Candida

KW - Caspofungin

KW - Micafungin

UR - http://www.scopus.com/inward/record.url?scp=0042134553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042134553&partnerID=8YFLogxK

U2 - 10.1517/13543784.12.8.1313

DO - 10.1517/13543784.12.8.1313

M3 - Article

C2 - 12882619

AN - SCOPUS:0042134553

VL - 12

SP - 1313

EP - 1327

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 8

ER -